Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Expert Perspectives in the Evolving Treatment Landscape for Follicular Lymphoma

October 12th 2020

Experts provide their perspectives on the evolving treatment landscape for patients with follicular lymphoma.

Lancet Oncology Data Reinforce Regulatory Approvals of Tazemetostat in Sarcoma, Follicular Lymphoma

October 9th 2020

Tazemetostat demonstrated durable responses and sustained safety in patients with epithelioid sarcoma and relapsed/refractory follicular lymphoma.

Current and Emerging Treatments in Follicular Lymphoma

October 9th 2020

Although the majority of patients with follicular lymphoma have a life expectancy similar to that of the general population, predicting which patients will relapse and finding therapies that provide durable responses in the relapsed or refractory setting remains an ongoing challenge.

Sequencing Challenges Arise Amid New Approvals in DLBCL Paradigm

October 5th 2020

Andrew M. Evens, DO, MSc, discusses the approval of 3 new regimens and how they have reformed the treatment paradigm of relapsed/refractory diffuse-large B-cell lymphoma.

Selinexor May Offer Post–CAR T Potential in Relapsed/Refractory DLBCL

September 30th 2020

Kami Maddocks, MD, discusses the significance of the selinexor approval in the diffuse large B-cell lymphoma treatment paradigm, emerging strategies that seek to address unmet needs, and remaining sequencing questions.

Dr. Pagel on Determining Treatment Based on Genetic Risk in Double- and Triple-Hit Lymphoma

September 29th 2020

John M. Pagel, MD, PhD, discusses the utility of rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone in double- and triple-hit lymphoma.

Dr. Skarbnik on Future Combination Therapies With Tazemetostat in Follicular Lymphoma

September 29th 2020

Alan P. Z. Skarbnik, MD, discusses future combination therapies with tazemetostat in follicular lymphoma.

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

September 29th 2020

BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemi; with 4 agents under examination in the space, selection will depend on availability, toxicity, convenience, and cost.

Dr. Skarbnik on the Approval of Tazemetostat in Relapsed/Refractory Follicular Lymphoma

September 28th 2020

Alan P. Z. Skarbnik, MD, highlights the approval of tazemetostat in relapsed/refractory follicular lymphoma.

Dr. Batlevi on the Role of Active Surveillance in Advanced-Stage Follicular Lymphoma

September 28th 2020

Connie L. Batlevi, MD, PhD, discusses the role of active surveillance in advanced-stage follicular lymphoma.

Dr. Burke on Risk Stratification Strategies in Follicular Lymphoma

September 28th 2020

John M. Burke, MD, discusses risk stratifications strategies in follicular lymphoma.

Precision Medicine Picks up Pace Across Oncology

September 28th 2020

Andre Goy, MD, MS, discusses how matching the right treatment with the right patient resides at the heart of precision medicine, but with continued interest in pursuing the molecular milieu of cancers, precision medicine has the potential to better inform pre- and post-cancer interventions as well.

Precision Medicine Challenges Deepen in DLBCL As Subtypes Emerge

September 28th 2020

Despite efforts to advance the precision oncology portfolio for patients with diffuse large B-cell lymphoma by categorizing subtypes of the molecularly heterogenous disease, developing treatment routes for these alternate forms presents an uphill battle.

Dr. Batlevi on Emerging Therapies in Follicular Lymphoma

September 25th 2020

Connie L. Batlevi, MD, PhD, discusses emerging therapies in follicular lymphoma.

Dr. Skarbnik on the Utility of PI3K Inhibitors in Follicular Lymphoma

September 25th 2020

Alan P. Z. Skarbnik, discusses ongoing research with PI3K inhibitors in follicular lymphoma.

Dr. Burke on Treatment Options in Relapsed/Refractory Follicular Lymphoma

September 25th 2020

John M. Burke, MD, discusses treatment options in relapsed/refractory follicular lymphoma.

Immune-Based Triplet Demonstrates Activity in Relapsed/Refractory DLCBL

September 25th 2020

The triplet regimen of atezolizumab, obinutuzumab, and venetoclax demonstrated encouraging activity and safety in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Ma on the Utility of BTK Inhibitors in Relapsed/Refractory CLL

September 24th 2020

Shuo Ma, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory chronic lymphocytic leukemia.

Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL

September 24th 2020

Erlene Seymour, MD, discusses the progression-free survival benefit with acalabrutinib with or without obinutuzumab in chronic lymphocytic leukemia.

Dr. Maddocks on Ongoing Sequencing Challenges in DLBCL

September 23rd 2020

Kami J. Maddocks, MD, discusses ongoing sequencing challenges in diffuse large B-cell lymphoma.